We are live on ! Find out more
AC

Aaron Cowen Suvretta Capital Management

AUM $5.47B
1-Year Est. Return 131.34%
 

Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.

This Fund
S&P 500
This Quarter Est. Return
+31.33%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$2.21B
AUM Growth
+$361M
Cap. Flow
-$44.8M
Cap. Flow %
-2.03%
Top 10 Hldgs %
47.06%
Holding
101
New
14
Increased
23
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$56.1M
2
TSM icon
TSMC
TSM
+$37M
3
GS icon
Goldman Sachs
GS
+$36.8M
4
APO icon
Apollo Global Management
APO
+$30.8M
5
FERG icon
Ferguson
FERG
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.28%
2 Technology 8.34%
3 Consumer Discretionary 5.97%
4 Communication Services 5.67%
5 Industrials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HZNP
101
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-786,313
Closed -$91M

Similar funds

Aaron Cowen's Q4 2023 Portfolio in Review

As of Q4 2023, Aaron Cowen held 101 positions worth $2.21B, up 20% from $1.85B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Aaron Cowen's Q4 2023 filing shows 14 new, 23 increased, 22 reduced and 13 closed positions. Its largest new stake was TSMC: 388,232 shares worth $40.4M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 65% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Aaron Cowen's largest Q4 2023 buy was TSMC: 388,232 shares worth $40.4M.
  • Aaron Cowen added most to Ultragenyx Pharmaceutical in Q4 2023, an estimated $56.1M increase.
  • Aaron Cowen's biggest Q4 2023 reduction was Advanced Micro Devices, cutting an estimated $42.8M.
  • Aaron Cowen fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $91M.
  • Aaron Cowen's ten largest holdings make up 47% of its $2.21B portfolio in Q4 2023.
  • Aaron Cowen opened 14 new positions and closed 13 in Q4 2023.
  • Aaron Cowen's portfolio value rose 20% quarter-over-quarter to $2.21B.

Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.